GGrantIndex
← Search

Cancer Biology

$48,413P30FY2017CANIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications, trials & patents

Paper 39764100Paper 39763867Paper 39605535Paper 39435649Paper 39386578Paper 39375962Trial NCT07434128Trial NCT07278440Trial NCT07089940Trial NCT05705492Trial NCT04247425Trial NCT04172493Trial NCT04104139Trial NCT04061980Trial NCT04005690Trial NCT03961672Trial NCT03960177Trial NCT03699995Trial NCT03677531Trial NCT03649880Trial NCT03626285Trial NCT03613259Trial NCT03544125Trial NCT03479268Trial NCT03418025Trial NCT03406013Trial NCT03361436Trial NCT03347617Trial NCT03325166Trial NCT03280277Trial NCT03270059Trial NCT03261180Trial NCT03234309Trial NCT03135782Trial NCT03097588Trial NCT03028935Trial NCT03010358Trial NCT03009201Trial NCT02890979Trial NCT02869412Trial NCT02857218Trial NCT02779283Trial NCT02736617Trial NCT02522715Trial NCT02504359Trial NCT02503358Trial NCT02501759Trial NCT02498951Trial NCT02427841Trial NCT02359097Trial NCT02355262Trial NCT02312557Trial NCT02228265Trial NCT02100189Trial NCT02099864Trial NCT02092324Trial NCT02070705Trial NCT02050919Trial NCT01913015Trial NCT01748942Trial NCT01689987Trial NCT01649505Trial NCT01635413Trial NCT01620216Trial NCT01532687Trial NCT01498978Trial NCT01441882Trial NCT01422408Trial NCT01253642Trial NCT01031953Trial NCT01005914Trial NCT00983398Trial NCT00978562Trial NCT00900302Trial NCT00900068Trial NCT00900055Trial NCT00899795Trial NCT00899522Trial NCT00843167Trial NCT00822848Trial NCT00764517Trial NCT00722072Trial NCT00691652Trial NCT00662103Trial NCT00660543Trial NCT00659126Trial NCT00627276Trial NCT00516542Trial NCT00482274Trial NCT00425386Trial NCT00324324Trial NCT00303849Trial NCT00293475Trial NCT00253721Trial NCT00253643Trial NCT00238433Trial NCT00227682Trial NCT00103038Trial NCT00075387Patent 9279811

Abstract

CANCER BIOLOGY PROGRAM Lisa M. Coussens, PhD, and Melissa Wong, PhD, Program Co-Leaders ABSTRACT Cancer Biology (CB) Program members explore genetic, molecular and cellular mechanisms underlying cancer initiation, progression, and response and resistance to therapy, providing platforms to translate basic science discoveries to clinical care. The program strives to gain insights into therapeutically-targetable pathways in neoplastic and host-derived cells within complex tumor microenvironments that drive malignancy. The program supports the overarching goal of the Knight Cancer Institute to understand the molecular and cellular basis of cancer and to translate these findings into precision clinical care. To accomplish these goals, the program is organized into three research themes: signal transduction (focused on cellular signaling mechanism relevant to homeostatic and neoplastic cell proliferation), carcinogenesis/genetic instability (examining cell intrinsic and extrinsic mechanisms that predispose to cancer, including regulation of cell-cycle checkpoint control, DNA damage and repair, and genetic and epigenetic alterations), and the tumor microenvironment (investigating mesenchymal support, immune, and vascular cell interactions with neoplastic cells). Program co-leader Melissa Wong, Ph.D., is an expert in stem cell biology, particularly in colorectal, breast and pancreas cancers. Co-leader Lisa M. Coussens, Ph.D., is an expert in the biology of microenvironmental regulation of solid tumorigenesis, with emphasis on cutaneous squamous, breast and pancreatic cancer. The 26 members are drawn from five basic science departments, three clinical departments or divisions in the OHSU School of Medicine, and four institutes affiliated with OHSU. Annual direct-cost funding as of January 2016 amounted to $14,666,464 (total cost), of which $6,250,223 (total cost) was from the NCI and $11,592,453 (total cost) was peer-reviewed. The discoveries made in this program have resulted in 202 publications, of which 12% are intra-programmatic collaborations and 28% are inter-programmatic collaborations, and 56% are inter-institutional.

View original record on NIH RePORTER →